Even a politician as tenaciously optimistic as Matt Hancock was struggling to put any positive spin on it: the world has woken up to the disappointing news that trials of the Oxford vaccine for Covid-19 had been paused after an adverse reaction in one patient. The Oxford-AstraZeneca vaccine was one of seven in Phase 3 trials, in which doses are administered to thousands of people of different ages and varying states of health.
Already a subscriber? Log in
Subscribe for just $2 a week
Try a month of The Spectator Australia absolutely free and without commitment. Not only that but – if you choose to continue – you’ll pay just $2 a week for your first year.
- Unlimited access to spectator.com.au and app
- The weekly edition on the Spectator Australia app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Don't miss out
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
SUBSCRIBEAlready a subscriber? Log in